LAS VEGAS, NV—First-in-human data from a novel tool to monitor bleeding show that it has the potential to heighten awareness and prevent or reduce the progression of subclinical bleeding during or ...

The primary efficacy endpoint of clinically-relevant bleeding, defined as BARC types 2, 3 or 5 bleeding, was assessed in the intention-to-treat population between one-month and twelve-months post-PCI ...